Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
March 18, 2025 06:50 ET
|
Eton Pharmaceuticals
Management to Hold Investor Day Conference Call Today at 10:00am ET Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16th straight...
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
March 14, 2025 06:50 ET
|
Eton Pharmaceuticals
- Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study -- Company expects to submit New Drug Application (NDA) in April 2025 - DEER PARK, Ill., March 14,...
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
March 04, 2025 06:50 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., March 04, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and...
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
March 03, 2025 06:50 ET
|
Eton Pharmaceuticals
– Eton expects to significantly expand patient access to this critical treatment for Wilson disease patients –– $0 co-pay for all eligible patients and best-in-class patient support services –– Now...
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
February 07, 2025 06:50 ET
|
Eton Pharmaceuticals
- Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange Book upon the product’s approval – DEER PARK, Ill., Feb. 07, 2025 ...
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
February 06, 2025 06:50 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
January 03, 2025 06:50 ET
|
Eton Pharmaceuticals
Adds an additional commercial and strategic rare disease product to Eton’s portfolioGalzin is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease DEER PARK, Ill.,...
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
December 20, 2024 06:50 ET
|
Eton Pharmaceuticals
Acquisition bolsters Eton’s commercial pediatric endocrinology portfolioProduct is now available through AnovoRx, a specialty pharmacy dedicated to serving patients with rare and chronic conditions ...
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
December 17, 2024 06:50 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
December 03, 2024 06:50 ET
|
Eton Pharmaceuticals
Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness...